Floatz logo

Zanubrutinib

Primary Central Nervous System Lymphoma

Explore 71 assets in Primary Central Nervous System Lymphoma →
Floatz Rating
B58/100
Confidence
Indicative
v0.2
Sponsor
Ruijin Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07405255CT.gov
Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma
—Not Yet Recruiting———
NCT06730542CT.gov
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
—Recruiting———
NCT06646211CT.gov
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
—Not Yet Recruiting———
NCT06445257CT.gov
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL
—Unknown———
NCT04938297CT.gov
Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
—Unknown———
NCT05398224CT.gov
R-MTX-zanbrutinib in Secondary CNS Lymphoma
—Unknown———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Primary Central Nervous System Lymphoma

AssetSponsorPhaseRating
Zanubrutinib (this asset)Ruijin HospitalP2B · 58
EtoposideFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyP4BBB
(+)-VincristineOno Pharmaceutical Co., Ltd.P4BBB
OrelabrutinibThe First Affiliated Hospital with Nanjing Medical UniversityP3BB
IdarubicinFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyP4BB
AdriamycinJuan P. Alderuccio, MDP4BB
DexasoneAllison WinterP4BB
CytarabineThe Lymphoma Academic Research OrganisationP4BB
RituximabOno Pharmaceutical Co., Ltd.P4BB

+42 more in the Primary Central Nervous System Lymphoma cohort

Other indications for Zanubrutinib

IndicationSponsorPhaseRating
B-Cell Non-Hodgkin Lymphoma—P4BBB · 73
Splenic Marginal Zone Lymphoma—P3BB · 68
Marginal Zone Lymphoma—P3BB · 67

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Zanubrutinib in Primary Central Nervous System Lymphoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/zanubrutinib-primary-central-nervous-system-lymphoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →